Business
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it will deliver an oral presentation and present multiple abstracts at the American Thoracic Society (ATS) 2026 International Conference, taking place from May 15 – 20, 2026, in Orlando, Florida.Oral Presentation Abstract: A Phase 2b Trial (CORAL) of Nalbuphine Extended-release Tablets in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough: Primary and Subgroup AnalysesOral Presentation Session: B95 Fibrosis, Cough, and Inflammation: Treatment Strategies in ILDDate & Time: May 18, 2:27 p.m. to 2:39 p.m. ETLocation: W304 E-H (Level III, OCCC West Concourse)Presenter: Philip L. Molyneaux, MD, PhD Poster Presentations Abstract: Pharmacokinetics and Safety Following Co-Administration of Nalbuphine Extended-Release with Pirfenidone or Nintedanib: A Phase 1 Drug-Drug Interaction StudyPoster Session: A75 Late Breaking Abstracts in Clinical ProblemsDate & Time: May 17, 11:30 a.m. to 1:15 p.m. ETLocation: Area L, Halls WA2-WA3 (Level I, OCCC West Concourse)Presenter: James Cassella, PhD Abstract: The Effect of Nalbuphine Extended Release on Cough Bouts in Patients with Idiopathic Pulmonary Fibrosis from a Phase 2b Randomized Clinical Trial (CORAL)Poster Session: A110 Closing the Gap: Advances in Pulmonary FibrosisDate & Time: May 17, 2:15 p.m. to 4:15 p.m. ETLocation: West F3 (Level II, OCCC...